SPRY4 regulates trophoblast proliferation and apoptosis via regulating IFN‐γ‐induced STAT1 expression and activation in recurrent miscarriage

摘要

Abstract Problem The dysregulation of trophoblast functions is one of the leading causes of recurrent miscarriage (RM), which frustrates 1%‐5% of couples of childbearing ages. Sprouty 4 (SPRY4) is considered as a tumour suppressor and exerts a negative role in cell viability. However, its role in regulating trophoblast behaviors at the maternal‐fetal interface remains largely unknown. Method of Study First‐trimester villous samples were collected from RM patients and healthy controls (HCs) to determine the SPRY4 expression in human placenta during early pregnancy. The HTR8/SVneo cell line was introduced to clarify trophoblast cell functions via transfecting with specific short interfering RNA against SPRY4 or SPRY4‐overexpressing lentivirus in vitro. In addition, gene expression microarray analysis was performed to explore the downstream molecules and pathways. Results Our results revealed that SPRY4 expression was significantly increased in the first‐trimester cytotrophoblasts of RM patients compared with HCs. Furthermore, SPRY4 overexpression inhibited trophoblast proliferation and accelerated apoptosis in vitro, while SPRY4 knockdown reversed these effects. Mechanistically, IFN‐γ ‐induced STAT1 expression and activation were involved in the regulation of trophoblast proliferation and apoptosis by SPRY4, and IFN‐γ promoted SPRY4 expression and STAT1 phosphorylation through PI3K/AKT pathway. Additionally, both STAT1 and phosphorylated STAT (p‐STAT) levels were also upregulated in trophoblasts from RM patients and positively correlated with SPRY4 expression. Conclusion Our findings indicate that SPRY4 may act as a negative regulator of trophoblast functions through upregulating IFN‐γ/PI3K/AKT‐induced STAT1 activation. High levels of SPRY4 and STAT1 may contribute to RM development and progression, and blocking of either target could be a novel therapeutic strategy for RM patients.